Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

被引：0
|
作者：
Liam, C. [1 ]
Ho, G. [2 ]
Chai, C. [3 ]
Alip, A. Bt [2 ]
Pang, Y. [1 ]
机构：
[1] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia
[2] Univ Malaya, Fac Med, Dept Oncol, Kuala Lumpur, Malaysia
[3] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Kota Samarahan, Malaysia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Real-world data; afatinib; T790M mutation;
D O I：
10.1016/j.jtho.2018.08.1897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.15-21
引用
收藏
页码：S998 / S999
页数：2
相关论文
共 50 条
  • [1] Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C. K.
    Chai, C.
    Ho, G.
    Alip, A.
    Wahid, M. I. A.
    Abdullah, M. M.
    Foo, Y. C.
    How, S. H.
    Zaatar, A.
    Lam, K. S.
    Leong, K. W.
    Low, J. S. H.
    Yusof, M. Md
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S848
  • [2] A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
    Yoon, S. H.
    Kim, Y. S.
    Chung, J. H.
    Seol, H. Y.
    Kim, M. H.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [3] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
    Cam Phuong Pham
    Thi Thai Hoa Nguyen
    Anh Tu Do
    Tuan Khoi Nguyen
    Thi Anh Thu Hoang
    Tuan Anh Le
    Dinh Thy Hao Vuong
    Dac Nhan Tam Nguyen
    Van Khiem Dang
    Thi Oanh Nguyen
    Van Luan Pham
    Minh Hai Nguyen
    Thi Huyen Trang Vo
    Hung Kien Do
    Ha Thanh Vu
    Thi Thuy Hang Nguyen
    Van Thai Pham
    Le Huy Trinh
    Khac Dung Nguyen
    Hoang Gia Nguyen
    Cong Minh Truong
    Tran Minh Chau Pham
    Thi Bich Phuong Nguyen
    [J]. BMC Cancer, 24
  • [4] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
    Pham, Cam Phuong
    Nguyen, Thi Thai Hoa
    Do, Anh Tu
    Nguyen, Tuan Khoi
    Hoang, Thi Anh Thu
    Le, Tuan Anh
    Vuong, Dinh Thy Hao
    Nguyen, Dac Nhan Tam
    Dang, Van Khiem
    Nguyen, Thi Oanh
    Pham, Van Luan
    Nguyen, Minh Hai
    Vo, Thi Huyen Trang
    Do, Hung Kien
    Vu, Ha Thanh
    Nguyen, Thi Thuy Hang
    Pham, Van Thai
    Trinh, Le Huy
    Nguyen, Khac Dung
    Nguyen, Hoang Gia
    Truong, Cong Minh
    Pham, Tran Minh Chau
    Nguyen, Thi Bich Phuong
    [J]. BMC CANCER, 2024, 24 (01)
  • [5] Real-world experience with afatinib as first-line treatment in advanced non-small cell lung cancer in a university hospital
    Jang, Taewon
    Kim, Jaehoon
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [6] Afatinib as First-Line Treatment in Elderly Patients with EGFR-Mutant Non-Small Cell Lung Cancer: Real-World Data Analysis
    Chen, Yen-Ting
    Yen, Chia-Te
    Wu, Wen-Jui
    Yang, Sheng-Hsiung
    [J]. INTERNATIONAL JOURNAL OF GERONTOLOGY, 2022, 16 (03) : 266 - 270
  • [7] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
    Lee, Sung Yong
    Choi, Chang-Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Choi, Juwhan
    Jang, Tae Won
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +
  • [8] Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Itoga, Masamichi
    Ishioka, Yoshiko
    Baba, Keisuke
    Shiratori, Toshihiro
    Sakamoto, Hiroaki
    Tsuchiya, Junichiro
    Nakagawa, Hideyuki
    Hasegawa, Yukihiro
    Yasugahira, Hideo
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    [J]. MEDICAL ONCOLOGY, 2019, 36 (06)
  • [9] Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
    Hisashi Tanaka
    Kageaki Taima
    Masamichi Itoga
    Yoshiko Ishioka
    Keisuke Baba
    Toshihiro Shiratori
    Hiroaki Sakamoto
    Junichiro Tsuchiya
    Hideyuki Nakagawa
    Yukihiro Hasegawa
    Hideo Yasugahira
    Koichi Okudera
    Shingo Takanashi
    Sadatomo Tasaka
    [J]. Medical Oncology, 2019, 36
  • [10] Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
    Shin, J. E.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1696 - S1697
12345